

• Contact • Print • Sitemap •  Search en | de



EVONIK  
INDUSTRIES

degussa

Home > EUDRAGIT > Sustained-release Formulations

Pharma Polymers

EUDRAGIT

Drug Delivery Technologies

Laboratories

Worldwide

Downloads

EUDRAGIT FS 30 D

Pharma Polymers

## EUDRAGIT® Power Through Flexibility

### EUDRAGIT

Quick Start

Emulsion Coatings

Sustained-release Formulations

Protective Coatings

Melt Extrusion

Regulatory & Toxicology

Packaging & Delivery

### Sustained-release Formulations

Sustained-release EUDRAGIT® formulations are employed for many oral dosage forms to enable time-controlled release of active ingredients. Drug delivery can be controlled throughout the whole gastro-intestinal tract for increased therapeutic effect and patient compliance. Different polymer combinations of EUDRAGIT® RL and RS grades allowing custom-tailored release profiles enable a wide range of alternatives to achieve the desired drug delivery performance. The EUDRAGIT® NE polymer is a neutral ester dispersion which requires no plasticizer and is particularly suitable for granulation processes in the manufacture of matrix tablets and sustained release coatings.

There are two formulation options:

- EUDRAGIT® is employed as a coating material, usually for the coating of pellets or particles that are filled into capsules or compressed into tablets. These pellets or particles act as diffusion cells in the digestive tract and release a constant drug quantity per unit of time (multi-unit dosage forms).
- EUDRAGIT® serves as a matrix by which the active ingredient is embedded. The matrix structure is obtained by direct compression, granulation, or melt techniques.

Applications	EUDRAGIT® Grades	Availability	Functionality	Dissolution Properties	Monographs & DMFs
Sustained release formulations	EUDRAGIT® RL 30 D	Aqueous dispersion 30%	Meth-/acrylates copolymers with trimethyl-aminomethylmethacrylate as a functional group	Insoluble High permeability pH independent swelling	Ph.Eur., USP/NF, JPE, DMF 1242
	EUDRAGIT® RL PO	Powder			
	EUDRAGIT® RL 100	Granules			
Sustained release formulations	EUDRAGIT® RS 30 D	Aqueous dispersion 30%	Neutral polymer of meth-/acrylates	Insoluble Low permeability pH independent swelling	Ph.Eur., USP/NF, JPE, DMF 1242
	EUDRAGIT® RS PO	Powder			
	EUDRAGIT® RS 100	Granules			
Sustained release formulations, suitable for matrix structures and miscible with other EUDRAGIT® grades	EUDRAGIT® NE 30 D	Aqueous dispersion 30%	Neutral polymer of meth-/acrylates	Insoluble Low permeability pH independent swelling	Ph.Eur., JPE, DMF 2822
	EUDRAGIT® NE 40 D	Aqueous dispersion 40%			
	EUDRAGIT® NE 60 D	Aqueous dispersion 60%			

### Application benefits of EUDRAGIT® coatings with sustained drug release:

- Time-controlled release of active ingredient
- Therapeutically optimized release profiles
- Higher patient compliance due to reduced number of doses to be taken
- Cost-effective processing

Imprint • Cookies • Privacy Statement • Disclaimer

**Degussa is now Evonik.**

Degussa is now Evonik.

As of September 12, 2007, what was Degussa is now the Chemicals Business Area of the new Evonik Industries. For further information on this creative new

<http://www.pharma-polymers.com/pharmapolymers/en/eudragit/sustainedreleaseform...> 2008/10/22